実践！　症例から学ぶ甲状腺疾患診療Q&A

出版社： 中外医学社
著者：
発行日： 2022-11-01
分野： 臨床医学：内科  >  内分泌/代謝
ISBN： 9784498123984
電子書籍版： 2022-11-01 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

4,840 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,840 円(税込)

購入する

商品紹介

若手医師が疑問に思うことについて，実際の症例から画像やデータをふんだんに用いた解説で臨床の様々なシチュエーションに対応できる力が身につく！　甲状腺をみる際に必要な疾患をすべて網羅！　専門病院が誇るエキスパートの技と考えかたを伝授した明日の診療に役立つ内容．

目次

  • 総　論
    　1　診断アプローチ：甲状腺膨大から
    　2　症状，検査所見から見た甲状腺機能異常
    　3　甲状腺関連の血液検査
    　4　図解：超音波検査
    　5　図解：甲状腺・副甲状腺シンチグラフィ
    　6　カウンセリング

    各　論
    甲状腺中毒症
    　1　Basedow病　薬の使い方
    　　　治療には無機ヨウ素をうまく使おう！
    　2　Basedow病　抗甲状腺薬の副作用　＜中泉伸彦，赤水尚史＞
    　　　抗甲状腺薬開始時は副作用モニタリングをしっかり行う！
    　3　Basedow病　T3優位型
    　　　FT3とFT4のバランスに注意しよう！
    　4　Basedow病患者の抗甲状腺薬中止
    　　　再燃について考えてみよう！
    　5　妊娠時一過性甲状腺機能亢進症
    　　　妊娠初期に甲状腺中毒症を見たら想起せよ！
    　6　機能性甲状腺結節　
    　　　その結節，甲状腺ホルモンを産生していますか？
    　7　卵巣甲状腺腫
    　　　甲状腺以外でもホルモン作っていませんか？
    　8　非自己免疫性甲状腺機能亢進症
    　　　稀な病気だが，決して忘れてはいけません！
    　9　潜在性甲状腺機能亢進症
    　　　いつから治療を始めますか？
    　10　外因性甲状腺中毒症
    　　　やせるサプリはやばい，やせないサプリは安全だ！

    甲状腺炎
    　11　無痛性甲状腺炎
    　　　 甲状腺中毒症の鑑別疾患でまず考えるのは？
    　12　亜急性甲状腺炎
    　　　 診断がついてもそれだけとは思わないで！
    　13　橋本病急性増悪
    　　　 急性増悪の症状，治療を知ろう！
    　14　急性化膿性甲状腺炎
    　　　 めずらしい甲状腺の細菌感染！
    　15　Riedel甲状腺炎
    　　　 石のように硬い甲状腺を触れたら？

    甲状腺機能低下症
    　16　橋本病（慢性甲状腺炎）
    　　 　不定愁訴と思う前に甲状腺機能をチェック！
    　17　Basedow病　131I内用療法後
    　　　 萎縮した甲状腺に適切な甲状腺ホルモン補充量は？
    　18　甲状腺全摘術後
    　　　 無甲状腺のホルモン状態と代謝の関連を知ろう！
    　19　ヨウ素過剰摂取
    　　　 問診でヨウ素摂取状態を把握しよう！
    　20　先天性甲状腺機能低下症（異所性）
    　　　 甲状腺はいったいどこにあるの？
    　21　先天性甲状腺機能低下症（TPO異常症）
    　　　 自己抗体陰性の甲状腺腫大から想起できる疾患は？
    　22　萎縮性甲状腺（TSBAb陽性）
    　　　 頻度は稀だが極めて対応が難しい！
    　23　中枢性甲状腺機能低下症
    　　　 甲状腺には原因のない甲状腺機能低下症に注意！
    　24　潜在性甲状腺機能低下症
    　　　 レボチロキシン（LT4）補充の適応はどう決める？

    甲状腺結節・腫瘍
    　25　多結節性甲状腺腫
    　　　 家族性多結節性甲状腺腫をきたす疾患を考えてみよう！
    　26　濾胞腺腫
    　　　 濾胞性腫瘍の手術適応を決定しよう！
    　27　甲状腺内胸腺癌
    　　　 胸腺様の分化を示す甲状腺腫瘍って何だ？
    　28　乳頭癌（微小癌）
    　　　 すべての微小癌が経過観察できるわけではないよ！
    　29　乳頭癌（リンパ節転移）
    　　　 乳頭癌のリンパ節転移の意味について考えよう！
    　30　乳頭癌（遠隔転移）
    　　　 乳頭癌の遠隔転移の対処について考えよう！
    　31　濾胞癌（微少浸潤型・被包性血管浸潤型）
    　　　 術前には確定診断できない悪性腫瘍！
    　32　濾胞癌（広汎浸潤）
    　　　 急に大きくならなくても油断はできない！
    　33　低分化癌
    　　　 再発，生命予後のよくない甲状腺癌に対処する！
    　34　未分化癌
    　　　 1日も無駄にせず診断，治療すれば治癒することもある！
    　35　髄様癌（散発性）
    　　　 散発性髄様癌の診断と治療方針を考えてみよう！
    　36　髄様癌（遺伝性）
    　　　 遺伝性髄様癌の診断と治療を考えてみよう！
    　37　リンパ腫
    　　　 急速に増大する甲状腺腫を診断しよう！

    その他
    　38　甲状腺ホルモン不応症
    　　　 真のSITSHの診断と，その鑑別疾患について知ろう！
    　39　免疫測定系への干渉
    　　　 検査値だけでBasedow病と誤診しないように！
    　40　甲状腺眼症
    　　　 Basedow病は治療後でも目に注意！
    　41　非甲状腺疾患（LowT3症候群）
    　　　 非甲状腺疾患の落とし穴！
    　42　薬剤性甲状腺機能異常
    　　　 甲状腺に影響する薬剤を知ろう！
    　43　原発性副甲状腺機能亢進症
    　　　 術前診断で治療の成否が決まる！

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

総論

P.6 掲載の参考文献
1) 七條小次郎. 地方性甲状腺腫. 日内分泌会誌. 1953 ; 29 : 155-88.
 
2) 深田修司, 編. 臨床で使える! 甲状腺疾患診療のテキスト. 日本医事新報社 ; 2019.
 
3) 深田修司, 総編集. 遺伝性甲状腺疾患のすべて. 日本医事新報社 ; 2021.
 
P.24 掲載の参考文献
1) 日本超音波医学会. 甲状腺結節 (腫瘤) 超音波診断基準 (2011年12月15日公示). 超音波医学. 2011 ; 38 : 667-8.
 
2) Yokozawa T, Fukata S, Kuma K, et al. Thyroid cancer detected by ultrasound-guided fine-needle aspiration biopsy. World J Surg. 1996 ; 20 : 848-53.
PubMed
3) 小林薫, 横澤保, 平井啓介, 他. 嚢胞内に突起を有する甲状腺乳頭癌-エコーガイド下細胞診による診断-. 内分泌外科. 1997 ; 14 : 285-90.
 
4) Kobayashi K, Fukata S, Amino N, et al. A case with diffuse sclerosing variant of papillary carcinoma of the thyroid : Characteristic features on ultrasonography. J Med Ultrasonics. 2006 ; 33 : 159-61.
 
5) Ota H, Ito Y, Matsuzuka F, et al. Usefulness of ultrasonography for diagnosis of malignant lymphoma of the thyroid. Thyroid 2006 ; 16 : 983-87.
PubMed
6) Kobayashi K, Fukata S, Miyauchi A. Diagnosis of follicular carcinoma of the thyroid : Role of sonography in preoperative diagnosis of follicular nodules. J Med Ultrasonics. 2005 ; 32 : 153-8.
 

各論

P.43 掲載の参考文献
1) Ota H, Amino N, Morita S, et al. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease. Clin Endocrinol (Oxf). 2007 ; 67 : 41-5.
PubMed
2) 日本甲状腺学会. 甲状腺疾患診断ガイドライン 2021 バセドウ病の診断ガイドライン. https://www.japanthyroid.jp/doctor/guideline/japanese.html#basedou
 
3) Takata K, Kubota S, Fukata S, et al. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid. 2009 ; 19 : 559-63.
 
4) Takata K, Amino N, Kubota S, et al. Benefit of short-term iodide supplementation to anti-thyroid drug treatment of thyrotoxicosis due to Graves' disease. Clin Endocrinol (Oxf). 2010 ; 72 : 845-50.
PubMed
5) Sato S, Noh JY, Sato S, et al. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism. Thyroid. 2015 ; 25 : 43-50.
 
6) 日本甲状腺学会, 編. バセドウ病治療ガイドライン 2019. 南江堂 ; 2019. p.56-7.
 
7) Kubota S, Amino N, Matsumoto Y, et al. Serial changes in liver function tests in patients with thyrotoxicosis induced by Graves' disease and painless thyroiditis. Thyroid. 2008 ; 18 : 283-7.
PubMed
P.47 掲載の参考文献
1) 日本甲状腺学会, 編. バセドウ病治療ガイドライン 2019. 南江堂 ; 2019. p.74-91.
 
2) 田尻淳一. 抗甲状腺薬の副作用を覚えておこう. In : 深田修司, 編. 臨床で使える! 甲状腺疾患診療のテキスト. 日本医事新報社 ; 2019. p.92-5.
 
3) Cooper DS. Treatment of thyrotoxicosis. In : Braverman LE, editors. Werner & Ingbar's the thyroid : a fundamental and clinical text, 11th ed. Wolters Kluwer ; 2020. p.501.
 
4) Noh JY, Yasuda S, Sato S, et al. Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by anti-thyroid drugs. J Clin Endocrinol Metab. 2009 ; 94 : 2806-11.
 
5) Nakamura H, Ide A, Kudo T, et al. Periodic granulocyte count measuring is useful for detecting asymptomatic agranulocytosis in anti-thyroid drug-treated patients with Graves' disease. Eur Thyroid J. 2016 ; 5 : 253-60.
 
6) Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from anti-thyroid drug-induced agranulocytosis : a prospective study. Thyroid. 1999 ; 9 : 29-31.
 
P.51 掲載の参考文献
1) Hashizume K, Ichikawa K, Sakurai A, et al. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med. 1991 ; 324 : 947-53.
PubMed
2) Takamatsu J, Sugawara M, Kuma K, et al. Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves' disease. Ann Intern Med. 1984 ; 100 : 372-5.
PubMed
3) Ito M, Toyoda N, Nomura E, et al. Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with 3,5,3'-triiodothyronine-predominant Graves' disease. Eur J Endocrinol. 2011 ; 164 : 95-100.
PubMed
4) Tamai H, Hayaki I, Kawai K, et al. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients. J Clin Endocrinol Metab. 1995 ; 80 : 1481-4.
PubMed
5) 高松順太. T3優位型バセドウ病. Modern Physician. 2003 ; 23 : 1087-90.
 
P.55 掲載の参考文献
1) 日本甲状腺学会, 編. バセドウ病治療ガイドライン 2019. 南江堂 ; 2019. p.49-50.
 
2) Kashiwai T, Hidaka Y, Takano T, et al. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease. Endocr J. 2003 ; 50 : 45-9.
PubMed
3) Konishi T, Okamoto Y, Ueda M, et al. Drug discontinuation after treatment with minimum maintenance dose of an anti-thyroid drug in Graves' disease : a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr J. 2011 ; 58 : 95-100.
 
4) Kubota S, Tamai H, Ohye H, et al. Transient hyperthyroidism after withdrawal of anti-thyroid drugs in patients with Graves' disease. Endocr J. 2004 ; 51 : 213-7.
 
5) Kim YA, Cho SW, Choi HS, et al. The second anti-thyroid drug treatment is effective in relapsed Graves' disease patients : a median 11-year follow-up study. Thyroid. 2017 ; 27 : 491-6.
 
P.59 掲載の参考文献
1) Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. N Engl J Med. 1994 ; 331 : 1072-8.
PubMed
2) Hershman JM. Human chorionic gonadotropin and the thyroid : hyperemesis gravidarum and trophoblastic tumors. Thyroid. 1999 ; 9 : 653-7.
PubMed
3) Yoshihara A, Noh JY, Mukasa K, et al. Serum human chorionic gonadotropin levels and thyroid hormone levels in gestational transient thyrotoxicosis : is the serum hCG level useful for differentiating between active Graves' disease and GTT? Endocr J. 2015 ; 62 : 557-60.
PubMed
P.63 掲載の参考文献
1) Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : The American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 ; 26 : 1-133.
PubMed
2) Biondi B, Bartalena L, Cooper DS, et al. The 2015 European Thyroid Association Guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015 ; 4 : 149-63.
PubMed
3) Nishihara E, Amino N, Maekawa K, et al. Prevalence of TSH receptor and Gsα mutations in 45 autonomously functioning thyroid nodules in Japan. Endocr J. 2009 ; 56 : 791-8.
 
4) Nishihara E, Amino N, Miyauchi A. Fractionated radioiodine therapy for hyperthyroidism caused by widespread metastatic follicular thyroid carcinoma. Thyroid. 2010 ; 20 : 569-70.
PubMed
5) Danno H, Nishihara E, Kousaka K, et al. Prevalence and treatment outcomes of Marine-Lenhart syndrome in Japan. Eur J Thyroid. 2021 ; 10 : 461-7.
PubMed
P.67 掲載の参考文献
1) Dunzendorfer T, deLas Morenas A, Kalir T, et al. Struma ovarii and hyperthyroidism. Thyroid. 1999 ; 9 : 499-502.
PubMed
2) DeSimone CP, Lele SM, Modesitt SC. Malignant struma ovarii : a case report and analysis of cases reported in the literature with focus on survival and I131 therapy. Gynecol Oncol. 2003 ; 89 : 543-8.
PubMed
P.71 掲載の参考文献
1) 深田修司, 編著. 臨床で使える! 甲状腺疾患診療のテキスト. 日本医事新報社 ; 2019. p.157-60.
 
2) Nishihara E, Chen CR, Higashiyama T, et al. Subclinical nonautoimmune hyperthyroidism in a family segregates with a thyrotropin receptor mutation with weakly increased constitutive activity. Thyroid. 2010 ; 20 : 1307-14.
 
3) Thomas JS, Leclere J, Hartemann P, et al. Familial hyperthyroidism without evidence of autoimmunity. Acta Endocrinol (Copenh). 1982 ; 100 : 512-8.
PubMed
4) Duprez L, Leclere J, Hartemann P, et al. Germline mutations in the thyrotropin receptor gene cause non-autoimmune auto-somal dominant hyperthyroidism. Nat Genet. 1994 ; 7 : 396-401.
 
5) Paschke R, Niedziela M, Vaidya B, et al. 2012 European thyroid association guidelines for the management of familial and persistent sporadic non-autoimmune hyperthyroidism caused by thyroid-stimulating hormone receptor germline mutations. Eur Thyroid J. 2012 ; 1 : 142-7.
PubMed
P.75 掲載の参考文献
1) Humburger JI. Evolution of toxicity in solitary nontoxic autonomously functioning thyroid nodules. J Clin Endocrinol Metab. 1980 ; 50 : 1089-93.
 
2) Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016 ; 26 : 1-133.
PubMed
3) Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 ; 26 : 1343-421.
PubMed
4) Ceccarelli C, Bencivelli W, Vitti P, et al. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules : a 20 years'retrospective study. Clin Endocrinol (Oxf). 2005 ; 62 : 331-5.
PubMed
P.79 掲載の参考文献
1) Ohye H, Fukata S, Kanoh M, et al. Thyrotoxicosis caused by weight-reducing herbal medicines. Arch Intern Med. 2005 ; 165 : 831-4.
PubMed
2) Hedberg CW, Fishbein DB, Janssen RS, et al. An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N Engl J Med. 1987 ; 316 : 993-8.
PubMed
3) Matsubara S, Inoh M, Tarumi Y, et al. An outbreak (159 cases) of transient thyrotoxicosis without hyperthyroidism in Japan. Intern Med. 1995 ; 34 : 514-9.
PubMed
4) Ishihara T, Nishikawa M, Ikekubo K, et al. Thyroxine (T4) metabolism in an athyreotic patient who had taken a large amount of T4 at one time. Endocr J. 1998 ; 45 : 371-5.
 
P.83 掲載の参考文献
1) Amino N, Tade H, Hidaka Y, et al. Postpartum autoimmune thyroid syndrome ; a model of aggravation of autoimmune disease. Thyroid. 1999 ; 9 : 705-13.
 
2) 網野信行, 藤原真子. 抗体 (TRAbTSH 受容体, TBII, TSAb). 日本臨牀 (増刊号). 2010 ; 68 : 305-8.
 
3) Hiraiwa T, Ito M, Imagawa A, et al. High diagnosis value of a radioiodine uptake test with and without iodine restriction in Graves' disease and silent thyroiditis. Thyroid. 2004 ; 14 : 531-5.
PubMed
4) Yoshimura Noh J, Momotani N, Fukada S, et al. Ratio of serum free triiodothyronine to free thyroxine in Graves' hyperthyroidism and thyrotoxicosis caused by painless thyroiditis. Endocrine J. 2005 ; 52 : 537-42.
 
P.87 掲載の参考文献
1) 日本甲状腺学会, 編. 亜急性甲状腺炎 (急性期) の診断ガイドライン. 甲状腺疾患診断ガイドライン 2021.
 
2) Nishihara E, Amino N, Kudo T, et al. Moderate frequency of anti-thyroglobulin antibodies in the early phase of subacute thyroiditis. Eur Thyroid J. 2019 ; 8 : 268-72.
PubMed
3) Nishihara E, Amino N, Ohye H, et al. Extent of hypoechogenic area in the thyroid is related with thyroid dysfunction after subacute thyroiditis. J Endocrinol Invest. 2009 ; 32 : 33-6.
PubMed
4) Kubota S, Nishihara E, Kudo T, et al. Initial treatment with 15 mg of prednisolone daily is sufficient for most patients with subacute thyroiditis in Japan. Thyroid. 2013 ; 23 : 269-72.
PubMed
5) Masuoka H, Miyauchi A, Tomoda C, et al. Imaging studies in sixty patients with acute suppurative thyroiditis. Thyroid. 2011 ; 21 : 1075-80.
PubMed
6) Nishihara E, Kudo T, Ito M, et al. Papillary thyroid carcinomas are highly obscured by inflammatory hypoechoic regions caused by subacute thyroiditis : a longitudinal evaluation of 710 patients using ultrasonography. Endocr J. 2020 ; 67 : 569-74.
PubMed
7) Nishihara E, Hirokawa M, Ohye H, et al. Papillary carcinoma obscured by complication with subacute thyroiditis : sequential ultrasonographic and histopathological findings in five cases. Thyroid. 2008 ; 18 : 1221-5.
PubMed
P.91 掲載の参考文献
1) Ishihara T, Mori T, Waseda N, et al. Histological, clinical and laboratory findings of acute exacerbation of Hashimoto's thyroiditis--comparison with those of subacute granulomatous thyroiditis. Endocrinol Jpn. 1987 ; 34 : 831-41.
PubMed
2) Shigemasa C, Ueta Y, Mitani Y, et al. Chronic thyroiditis with painful tender thyroid enlargement and transient thyrotoxicosis. J Clin Endocrinol Metab. 1990 ; 70 : 385-90.
PubMed
3) Ohye H, Fukata S, Kubota S, et al. Successful treatment for recurrent painful Hashimoto's thyroiditis by total thyroidectomy. Thyroid. 2005 ; 15 : 340-5.
PubMed
4) Fukata S, Matsuzuka F, Hara T, et al. Rapidly progressive thyroid failure in Graves' disease after painful attack in the thyroid grand. Arch Intern Med. 1993 ; 153 : 2157-61.
 
P.94 掲載の参考文献
1) Takai SI, Miyauchi A, Matsuzuka F, et al. Internal fistula as a route of infection in acute suppurative thyroiditis. Lancet. 1979 ; 1 : 751-2.
PubMed
2) Miyauchi A, Inoue H, Tomoda C, et al. Evaluation of chemocauterization treatment for obliteration of pyriform sinus fistula as a route of infection causing acute suppurative thyroiditis. Thyroid. 2009 ; 19 : 789-93.
 
3) Masuoka H, Miyauchi A, Tomoda C, et al. Imaging studies in sixty patients with acute suppurative thyroiditis. Thyroid. 2011 ; 21 : 1075-80.
PubMed
4) Masuoka H, Miyauchi A, Sasaki T, et al. Outcomes of endoscopic chemo- and laser-cauterizations and open fistulectomy for pyriform sinus fistula. J Otolaryngol Head Neck Surg. 2021 ; 50 : 49.
PubMed
P.99 掲載の参考文献
1) Henry I, et al. Riedel's thyroiditis a review and report of two cases. Am J Surg ; 1941. p.472-8.
 
2) Hennessey JV. Clinical review : Riedel's thyroiditis : a clinical review. J Clin Endocrinol. 2011 ; 96 : 3031-41.
 
3) Fatourechi MM, Hay ID, Mclver B, et al. Invasive fibrous thyroiditi (s Riedel thyroiditis) : the Mayo Clinic experience, 1976-2008. Thyroid. 2011 ; 21 : 765-72.
 
P.105 掲載の参考文献
1) Mariotti S, Caturegli P, Piccolo P, et al. Antithyroid peroxidase autoantibodies in thyroid diseases. J Clin Endocrinol Metab. 1990 ; 71 : 661-9.
PubMed
2) Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults : Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012 ; 18 : 988-1028.
 
3) Nishihara E, Amino N, Kudo T, et al. Comparison of thyroglobulin and thyroid peroxidase antibodies measured by five different kits in autoimmune thyroid diseases. Endocr J. 2017 ; 64 : 955-61.
PubMed
4) Pederson IB, Knudsen N, Carle A, et al. A cautious iodization programme bringing iodine intake to a low recommended level is associated with an increase in the prevalence of thyroid autoantibodies in the population. Clin Endocrinol (Oxf). 2011 ; 75 : 120-6.
 
5) Bliddal S, Boas M, Hilsted L, et al. Increase in thyroglobulin antibody and thyroid peroxidase antibody levels, but not preterm birthrate, in pregnant Danish women upon iodine fortification. Eur J Endocrinol. 2017 ; 176 : 603-12.
PubMed
6) Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism : prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014 ; 24 : 1670-751.
PubMed
7) 高須信行. 橋本病甲状腺機能低下症-低下症からの回復. 深田修司, 編. 臨床で使える! 甲状腺疾患診療のテキスト. 日本医事新報社 ; 2019. p.221-2.
 
P.109 掲載の参考文献
1) Kubota S, Ohye H, Yano G, et al. Two-day thionamide withdrawal prior to radioiodine uptake sufficiently increases uptake and does not exacerbate hyperthyroidism compared to 7-day withdrawal in Graves' disease. Endocr J. 2006 ; 53 : 603-7.
 
2) Ito M, Kawasaki M, Danno H, et al. Serum thyroid hormone balance in levothyroxine monotherapy-treated patients with atrophic thyroid after radioiodine treatment for Graves' disease. Thyroid. 2019 ; 29 : 1364-70.
PubMed
3) Ito M, Miyauchi A, Hisakado M, et al. Biochemical markers reflecting thyroid function in athyreotic patients on levothyroxine monotherapy. Thyroid. 2017 ; 27 : 484-90.
PubMed
P.113 掲載の参考文献
1) 日本内分泌外科学会, 日本甲状腺外科学会. 甲状腺腫瘍診療ガイドライン 2018. 日本内分泌・甲状腺外科学会雑誌. 2018 ; 35 増刊 : 1-87.
 
2) Ito M, Miyauchi A, Morita S, et al. TSH-suppressive doses of levothyroxine are required to achieve preoperative native serum triiodothyronine levels in patients who have undergone total thyroidectomy. Eur J Endocrinol. 2012 ; 167 : 373-8.
PubMed
3) Ito M, Miyauchi A, Hisakado M, et al. Biochemical markers reflecting thyroid function in athyreotic patients on levothyroxine monotherapy. Thyroid. 2017 ; 27 : 484-90.
PubMed
4) Ito M, Miyauchi A, Hisakado M, et al. Thyroid function related symptoms during levothyroxine monotherapy in athyreotic patients. Endocr J. 2019 ; 66 : 953-60.
PubMed
P.117 掲載の参考文献
1) Zimmermann MB, Teng W. Iodine deficiency and excess, endemic cretinism. In : Braverman LE, et al, editors. Werner & Ingbar's the thyroid : a fundamental and clinical text, 11th ed. Wolters Kluwer ; 2020. p.244-9.
 
2) Markou K, Georgopoulos N, Kyriazopoulou V, et al. Iodine-induced hypothyroidism. Thyroid. 2001 ; 11 : 501.
PubMed
3) 厚生労働省. 「日本人の食事摂取基準」策定検討会. ヨウ素 (I) : 日本人の食事摂取基準 (2020年版). 2020. p.335-40.
 
4) Fuse Y. Current medical topics and problems on iodine-An unique pattern of iodine nutrition in Japanese. Biomed Res Trace Elements. 2013 ; 24 : 117-52.
 
5) World Health Organization. Urinary iodine concentrations for determining iodine status in populations. Vitamin and Mineral Nutrition Information System. Geneva : World Health Organization ; 2013. https://www.who.int/publications/i/item/WHO-NMH-NHD-EPG-13.1
 
6) 文部科学省. 日本食品標準成分表 2020年版 (八訂). https://fooddb.mext.go.jp/
 
7) 西川光重. ヨウ素誘発性甲状腺腫. 日本臨牀別冊 内分泌症候群 (第3版) -その他の内分泌疾患を含めて-内分泌症候群 I 日本臨牀社 ; 2018. p.468-73.
 
P.121 掲載の参考文献
1) 先天性甲状腺機能低下症マス・スクリーニングガイドライン (2021年改訂版). http://jspe.umin.jp/medical/gui.html
 
2) Leger J, Olivieri A, Donaldson M, et al. European society for paediatric endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. J Clin Endocrinol Metab. 2014 ; 99 : 363-84.
PubMed
3) van Trotsenburg P, Stoupa A, Leger J, et al. Congenital hypothyroidism : A 2020-2021 consensus guidelines update-An ENDO-European reference network initiative endorsed by the European society for pediatric endocrinology and the European society for endocrinology. Thyroid. 2021 ; 31 : 387-419.
PubMed
4) Marinovic D, Garel C, Czernichow P, et al. Additional phenotypic abnormalities with presence of cysts within the empty thyroid area in patients with congenital hypothyroidism with thyroid dysgenesis. J Clin Endocrinol Metab. 2003 ; 88 : 1212-6.
PubMed
5) Nagasaki K, Asami T, Ogawa Y, et al. A study of the etiology of congenital hypothyroidism in the Niigata prefecture of Japan in patients born between 1989 and 2005 and evaluated at ages 5-19. Thyroid. 2011 ; 21 : 361-5.
 
P.125 掲載の参考文献
1) 菱沼昭. 遺伝性甲状腺疾患の概論. In : 深田修司, 他編. 遺伝性甲状腺疾患のすべて. 日本医事新報社 ; 2021. p.11-7.
 
2) Fukata S, Hishinuma A, Kuma K, et al. Endemic goiter due to thyroglobulin gene abnormality and social ostracism. Endocr J. 2007 : 54 : 485-6.
PubMed
3) Narumi S, Muroya K, Asakura Y, et al. Molecular basis of thyroid dyshormonogensis : genetic screening in population-based Japanese patients. J Clin Endocrinol Metab. 2011 : 96 : E1838-42.
 
4) Narumi S, Fox LA, Fukudome K, et al. Mild thyroid perocidase deficiency caused by TPO mutations with residual activity : Correlation between clinical phenotypes and enzymatic activity. Endocr J. 2017 : 64 : 1087-97.
 
P.129 掲載の参考文献
1) 笠木寛治, 蛭間真梨乃, 渡邊奈津子, 他. TSBAb測定の臨床的有用性と限界-改良法ヤマサキットの使用経験-. 日本甲状腺学会雑誌. 2018 ; 9 : 172-9.
Medical*Online
2) 日本小児内分泌学会マス・スクーリング委員会, 日本マス・スクリーニング学会. 先天性甲状腺機能低下症マス・スクリーニングガイドライン. 2014年改訂版.
 
P.133 掲載の参考文献
1) 日本甲状腺学会, 編. 甲状腺専門医ガイドブック 改訂第2版, 診断と治療社 ; 2017. p.171-7.
 
2) Fujii M, Nakagawa A, Tachibana O, et al. Anterior pituitary function in Rathke's cleft cysts versus nonfunctioning pituitary adenomas. Endocr J. 2021 ; 68 : 943-52.
PubMed
3) Braverman LE, Cooper DS, Kopp P, editors. Werner & Ingbar's the thyroid, 11th ed. Wolters Kluwer ; 2021. p.566-74.
 
4) 日本内分泌学会, 編. 間脳下垂体機能障害の診断と治療の手引き (平成30年度改訂). 日内分泌会誌. 2019 ; 95 : 1-60.
 
P.137 掲載の参考文献
1) Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017 ; 27 : 315-89.
PubMed
2) Yoshioka W, Amino N, Ide A, et al. Thyroxine treatment may be useful for subclinical hypothyroidism in patients wih female infertility. Endocr J. 2015 ; 62 : 87-92.
 
3) Hattori N, Ishihara T, Yamagami K, et al. Macro TSH in patients with subclinical hypothyroidism. Clin Endocrinol. 2015 ; 83 : 923-30.
PubMed
4) Ito M, Arishima T, Kudo T, et al. Effect of levo-thyroxine replacement on non-high-density lipoprotein cholesterol in hypothyroid patients. J Clin Endocrinol Metab. 2007 ; 92 : 608-11.
PubMed
5) Peeters RP. Subclinical hypothyroidism. N Engl J Med. 2017 ; 37 : 1404.
 
P.143 掲載の参考文献
1) Medeiros-Neto G. Multinodular goiter. Thyroid manager. 2016.
 
2) Teshiba R, Tajiri T, Sumitomo K, et al. Identification of a KEAP1 germline mutation in a family with multinodular goitre. PLoS One. 2013 ; 8 : e65141.
 
3) Nishihara E, Hishinuma A, Kogai T, et al. A novel germline mutation of KEAP1 (R483H) associated with a non-toxic multinodular goiter. Frontiers in Endocrinology. 2016 ; 7 : 131.
PubMed
P.147 掲載の参考文献
1) Yokozawa T, Fukata S, Kuma K, et al. Thyroid cancer detected by ultrasound-guided fine-needle aspiration biopsy. World J Surg. 1996 ; 20 : 848-53.
PubMed
2) Kihara M, Hirokawa M, Masuoka H, et al. Evaluation of cytologically benign solitary thyroid nodules by ultrasonography : a retrospective analysis of 1877 cases. Auris Nasus Larynx. 2013 ; 40 : 308-11.
PubMed
3) Kihara M, Miyauchi A, Hirokawa M, et al. Long-term outcomes of cytologically benign thyroid tumors : a retrospective analysis of 3,102 patients at a single institution. Endocr J. 2021. (in press)
 
4) Nakamura H, Hirokawa M, Ota H, et al. Is an increase in thyroid nodule volume a risk factor for malignancy? Thyroid. 2015 ; 25 : 804-11.
PubMed
P.151 掲載の参考文献
1) Miyauchi A, Kuma K, Matsuzuka F, et al. Intrathyroidal epithelial thymoma : an entity distinct from squamous cell carcinoma of the thyroid. World J Surg. 1985 ; 9 : 128-35.
PubMed
2) Ito Y, Miyauchi A, Nakamura Y, et al. Clinicopathologic significance of intrathyroidal epithelial thymoma/carcinoma showing thymus-like differentiation. Am J Clin Pathol. 2007 ; 127 : 230-6.
PubMed
3) Hirokawa M, Kuma S, Miyauchi A, et al. Cytological findings of intrathyroidal epithelial thymoma/carcinoma showing thymus-like differentiation : A study of eight cases. Diagn Cytopathol. 2012 ; 40 (Suppl 1) : E16-20.
 
P.154 掲載の参考文献
1) Ito Y, Miyauchi A, Inoue H, et al. An observation trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2010 ; 34 : 28-35.
PubMed
2) Ito Y, Miyauchi A, Kihara M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014 ; 24 : 27-34.
 
3) Sugitani I, Toda K, Yamada K, et al. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized : our treatment strategies and outcomes. World J Surg. 2010 ; 34 : 1222-31.
PubMed
4) Ito Y, Miyauchi A, Oda H, et al. Revisiting low-risk thyroid papillary microcarcinomas resected without observation : Was immediate surgery necessary? World J Surg. 2016 ; 40 : 523-8.
PubMed
5) 日本内分泌外科学会甲状腺微小癌取扱い委員会. 成人の甲状腺低リスク微小乳頭癌cT1aN0M0に対する積極的経過観察の適応と方法. http://jaes.umin.jp/pdf/news2020033101.pdf
 
6) Sugitani I, Ito Y, Takeuchi D, et al. Indications and strategy for active surveillance of adult low-risk papillary thyroid microcarcinoma : Consensus statements from the Japan association of endocrine surgery task force on management for papillary thyroid microcarcinoma. Thyroid. 2021 ; 31 : 183-92.
PubMed
P.159 掲載の参考文献
1) Ito Y, Fukushima M. Tomoda C, et al. Prognosis of patients with papillary thyroid carcinoma having clinically apparent metastasis to the lateral compartment. Endocr J. 2009 ; 56 : 759-66.
 
2) Uruno T, Miyauchi A, Shimizu K, et al. Usefulness of thyroglobulin measurement in fine-needle aspiration biopsy specimens for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer. World J Surg. 2005 ; 29 : 483-5.
PubMed
3) Ito Y, Miyauchi A, Kihara M, et al. Overall survival of papillary thyroid carcinoma patients : a single-institution long-term follow-up of 5897 patients. World J Surg. 2018 ; 42 : 615-22.
PubMed
4) Schlumberger M, Baudin E, Travagli JP. Papillary and follicular cancers of the thyroid. Presse Med. 1998 ; 27 : 1479-81.
PubMed
5) Lee N, Tuttle M. The role of external beam radiotherapy in the treatment of papillary thyroid cancer. Endocr Relat Cancer. 2006 ; 13 : 971-7.
PubMed
P.163 掲載の参考文献
1) Ito Y, Miyauchi A, Hirokawa M, et al. Prognostic value of the 8th edition of the tumor-node-metastasis classification for patients with papillary thyroid carcinoma : a single-institution study at a high-volume center in Japan. Endocr J. 2018 ; 65 : 707-16.
 
2) Ito Y, Miyauchi A, Kihara M, et al. Overall survival of papillary thyroid carcinoma patients : a single-institution long-term follow-up of 5897 patients. World J Surg. 2018 ; 42 : 615-22.
PubMed
3) Miyauchi A, Kudo T, Miya A, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011 ; 21 : 707-16.
PubMed
4) Ito Y, Onoda N, Okamoto T. The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons : Core questions and recommendations for treatments of thyroid cancer. Endocr J. 2020 ; 67 : 669-717.
PubMed
P.167 掲載の参考文献
1) 日本内分泌外科学会・日本甲状腺病理学会, 編. 甲状腺癌取扱い規約 第8版. 金原出版 ; 2019. p.18.
 
2) 伊藤康弘, 宮内昭. 濾胞癌の治療成績と予後因子. 日本内分泌・甲状腺外科学会誌. 2017 ; 34 : 160-5.
 
3) Ito Y, Hirokawa M, Miyauchi A, et al. Prognostic impact of Ki-67 labeling index in minimally invasive follicular thyroid carcinoma. Endocr J. 2016 ; 63 : 913-7.
PubMed
P.171 掲載の参考文献
1) 日本内分泌外科学会・日本甲状腺病理学会, 編. 甲状腺癌取扱い規約 第8版. 金原出版 ; 2019. p.18.
 
2) Ito Y, Hirokawa M, Higashiyama T, et al. Prognosis and prognostic factors of follicular carcinoma in Japan : importance of postoperative pathological examination. World J Surg. 2007 ; 31 : 1417-24.
PubMed
3) 伊藤康弘, 宮内昭. 濾胞癌の治療成績と予後因子. 日本内分泌・甲状腺外科学会誌. 2017 ; 34 : 160-5.
 
4) Ito Y, Hirokawa M, Fujishima M, et al. Prognostic significance of vascular invasion and cell-proliferation activity in widely invasive follicular carcinoma of the thyroid. Endcrine J. 2021 ; 68 : 881-8.
 
P.175 掲載の参考文献
1) Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer. 1983 ; 52 : 1849-55.
PubMed
2) 日本内分泌外科学会・日本甲状腺病理学会, 編. 甲状腺癌取扱い規約 第8版. 金原出版 : 2019.
 
3) Ito Y, Hirokawa M, Miyauchi A, et al. Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan. World J Surg. 2008 ; 32 : 1535-43.
PubMed
P.179 掲載の参考文献
1) 甲状腺腫瘍診療ガイドライン作成委員会. 甲状腺腫瘍診療ガイドライン 2018. 日本内分泌・甲状腺外科学会誌. 2018 ; 35 : 42-5.
 
2) Ito Y, Higashiyama T, Miyauchi A et al. Investigation of the validity of UICC stage grouping of anaplastic carcinoma of the thyroid. Asian J Surg. 2009 ; 32 : 47-50.
PubMed
3) Higashiyama T, Ito Y, Hirokawa M, et al. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid. 2010 ; 20 : 7-14.
PubMed
4) Onoda N, Sugino K, Higashiyama T, et al. The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients : A nationwide prospective study. Thyroid. 2016 ; 26 : 1293-9.
PubMed
5) Higasiyama T, Sugino K, Hara H, et al. Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). Eur J Cancer. 2022 ; 173 : 210-8.
 
6) Wang JR, Zafereo ME, Dadu R, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF V600E-mutated anaplastic thyroid carcinoma. Thyroid. 2019 ; 29 : 1036-43.
PubMed
P.183 掲載の参考文献
1) Kudo T, Miyauchi A, Ito Y, et al. Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. Thyroid. 2007 ; 17 : 635-8.
PubMed
2) Kihara M, Miyauchi A, Kudo T, et al. Serum calcitonin reference values for calcium stimulation tests by electrochemiluminescence immunoassay in Japanese men with non-medullary thyroid carcinoma. Surg Today. 2018 ; 48 : 223-8.
PubMed
3) Kihara M, Miyauchi A, Kudo T, et al. Reference values of serum calcitonin with calcium stimulation tests by electrochemiluminescence immunoassay before/after total thyroidectomy in Japanese patients with thyroid diseases other than medullary thyroid carcinoma. Endocr J. 2016 ; 63 : 627-32.
PubMed
4) Miyauchi A, Matsuzuka F, Hirai K, et al. Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg. 2002 ; 26 : 1023-8.
PubMed
5) Ito Y, Miyauchi A, Kihara M, et al. Static prognostic factors and appropriate surgical designs for patients with medullary thyroid carcinoma : The second report from a single-institution study in Japan. World J Surg. 2018 ; 42 : 3954-66.
PubMed
P.187 掲載の参考文献
1) Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Thyroid. 2015 ; 25 : 567-610.
PubMed
2) 木原実. MEN2の予防的甲状腺全摘. 内分泌甲状腺外会誌. 2017 ; 34 : 41-4.
 
P.191 掲載の参考文献
1) 東山卓也, 宮内 昭. 甲状腺悪性リンパ腫の予後因子. 日内分泌外会誌. 2019 ; 36 : 171-5.
 
2) Hirokawa M, Kudo T, Ota H, et al. Preoperative diagnostic algorithm of primary thyroid lymphoma using ultrasound, aspiration cytology, and flow cytometry. Endocr J. 2017 ; 64 : 859-65.
 
P.195 掲載の参考文献
1) Barkoff MS, Kocherginsky M, Anselmo J, et al. Autoimmunity in patients with resistance to thyroid. J Clin Endocrinol Metab. 2010 ; 95 : 3189-93.
PubMed
2) Okazaki-Hada M, Nishihara E, Hisakado M, et al. Autoimmune thyroid disease and thyroid function test fluctuations in patients with resistance to thyroid hormone. Eur J Endocrinol. 2021 ; 186 : 73-82.
PubMed
3) Refetoff S. Impared sensitivity to thyroid hormone : defects of transport, metabolism, and action. Werner & Ingbar's the thyroid, Breverman LE, et al, editors. Philadelphia : Lippincott Williams & Wilkins ; 2020. p.868-907.
 
4) Dumitrescu AM, Refetoff S. Impaired sensitivity to thyroid hormone : defects of transport, metabolism and action. Endotext [Internet]. South Dartmouth (MA) : MDText. com ; 2000-2015.
 
5) Bochukova E, Schonmakers N, Agostini M, et al. A mutation in the thyroid hormone receptor alpha gene. N Engl J Med. 2012 ; 366 : 243-9.
 
6) 日本甲状腺学会. 甲状腺ホルモン不応症 (RTHβ) 診断基準ならびに重症度分類 (第2次案). 2016. http://www.japanthyroid.jp/doctor/img/hormone03.pdf?20210506
 
P.199 掲載の参考文献
1) 村田善晴. 甲状腺ホルモン不応症の診断基準作成. 日本甲状腺学会誌. 2012 ; 3 ; 10-4.
 
2) Gulbahar O, Konca Degertekin C, Akturk M, et al. A case with immunoassay interferences in the measurement of multiple hormones. J Clin Endocrinol Metab. 2015 ; 100 : 2147-53.
PubMed
3) Ohba K, Noh JY, Unno T, et al. Falsely elevated thyroid hormone levels caused by anti-ruthenium interference in the Elecsys assay resembling the syndrome of inappropriate secretion of thyrotropin. Endocrine J. 2012 ; 59 : 663-7.
 
4) Samarasinghe S, Meah F, Singh V, et al. Biotin interference with routine clinical immunoassays : Understand the causes and mitigate the risks. Endocr Pract. 2017 ; 23 : 989-98.
PubMed
5) Peltier L, Massart C, Moineau MP, et al. Anti-streptavidin interferences in Roche thyroid immunoassays : a case report. Clin Chem Lab Med. 2016 ; 54 : e11-4.
PubMed
6) 日本甲状腺学会. 甲状腺ホルモン不応症 (RTHβ) 診断基準ならびに重症度分類 (第2次案). 2016.
 
P.203 掲載の参考文献
1) 深田修司. 隈病院, TRAbとTSAbの乖離を追跡できたバセドウ病眼症の1例. 第93回日本内分泌学会学術総会.
 
2) Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008 ; 158 : 273-85.
 
3) 日本甲状腺学会. バセドウ病悪性眼球突出症の診断基準と治療指針, 2018.
 
P.207 掲載の参考文献
1) 橋本貢士, 森昌朋. 甲状腺ホルモンの合成と分泌の機構. 綜合臨牀. 2009 ; 58 : 1491-8.
Medical*Online
2) Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronoary artery bypass surgery. N Engl J Med. 1995 ; 333 : 1522-7.
 
3) Boelen A, Langouche L, Wiersinga W, et al. Nonthyroidal illness syndrome. In : Braverman LE, et al, editors. Ingbar & Werner's the tyroid. 11th ed. Wolters Kluwer ; 2021. p.214-29.
 
P.211 掲載の参考文献
1) 西川光重. 甲状腺機能に影響を及ぼす薬剤. In : 深田修司, 編. 臨床で使える! 甲状腺疾患診療のテキスト. 日本医事新報社 : 2019. p.25-8.
 
2) Sarne D. Effects of drugs on TSH secretion, thyroid hormone's absorption, synthesis, metabolism, and action. In : Braverman LE, et al, editors. Ingbar & Werner's the thyroid 11th ed. Philadelphia ; Wolters Kluwer : 2021. p.190-202.
 
3) 西原永潤. 分子標的薬による甲状腺機能障害. 内分泌・糖尿病・代謝内科. 2019 ; 49 : 110-4.
 
P.216 掲載の参考文献
1) Hirokawa M, Suzuki A, Miyauchi A, et al. Histological alterations following fine-needle aspiration for parathyroid adenoma : Incidence and diagnostic problems. Pathol Int. 2021 (in press).
 
2) Suzuki A, Hirokawa M, Miyauchi A, et al. Fine-needle aspiration of parathyroid adenomas : Indications as a diagnostic approach. Diagn Cytopathol. 2021 ; 49 : 70-6.
PubMed

書評

最近チェックした商品履歴

Loading...